The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
GlobalData on MSN2d
FDA greenlights Regeneron’s Dupixent for the treatment of COPDWith an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
Researchers from Teesside University and the National Institute for Health and Care Research (NIHR) Applied Research ...
Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...
N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.
Hosted on MSN17d
Early signs of lung disease you shouldn’t ignoreRecognising early warning signs of lung disease is vital for timely intervention and treatment. Persistent Cough A cough ... Chronic coughing could signal chronic obstructive pulmonary disease (COPD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback